{
    "clinical_study": {
        "@rank": "82273", 
        "arm_group": [
            {
                "arm_group_label": "omega-3 DHA", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this group will receive 500 mg/day supplement of DHA omega-3 fatty acid in capsule form, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients in this group will receive an placebo capsule, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme"
            }
        ], 
        "brief_summary": {
            "textblock": "Comparative, randomized, placebo-controlled, single-centre, single-blind clinical trial to\n      assess the effectiveness of providing additional DHA omega-3 fatty acids  supplements to\n      increase the levels of pro-resolving and anti-inflammatory lipid mediators and decrease the\n      biological markers of chronic inflammation in obese patients following a weight-loss\n      programme."
        }, 
        "brief_title": "Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Obesity", 
            "Inflammation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Obesity", 
                "Weight Loss"
            ]
        }, 
        "detailed_description": {
            "textblock": "Will include obese patients (BMI between 30 and 35) who are following a standardized,\n      multidisciplinary weight-loss programme (PronoKal\u00ae Method), which consists of a\n      very-low-calorie diet based on protein packets and vegetables with a low glycemic index,\n      into which natural foods are gradually reintroduced, accompanied by physical exercise and\n      emotional support.\n\n      Patients who are being treated with acetylsalicylic acid (ASA), non-steroidal\n      anti-inflammatory drugs (NSAIDS), corticoids or thiazolidinedione antidiabetic drugs\n      (glitazones); and patients with immune disorders (rheumatoid arthritis, Lupus, etc.) and/or\n      inflammatory disease (ulcerative colitis, Crohn's disease, etc.) who may alter the\n      biological markers of inflammation,will be excluded.\n\n      Treatment: In addition to the vitamin and oligoelement supplements which are part of the\n      standard weight-loss programme, the patients will receive an additional 500 mg/day\n      supplement of DHA omega-3 fatty acids in capsule form (study group) or a placebo capsule\n      (control group).\n\n      The follow up will be 6 months and patients will be monitored over the course of 6 control\n      visits: baseline, 7 days, 15 days, 30 days, 60 days and 180 days.\n\n      The main objective is to assess the effectiveness of providing additional DHA supplements to\n      increase the levels of pro-resolving and anti-inflammatory lipid mediators and decrease the\n      biological markers of chronic inflammation in obese patients following a weight-loss\n      programme."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 18 and 75 years\n\n          -  Obese patients with Body Mass Index between 30 and 35\n\n          -  Patients who, regardless of their inclusion in this study, are going to follow the\n             standardized weight-loss programme (PronoKal\u00ae Method)\n\n          -  Patients who agree to participate and sign the Informed Consent form\n\n        Exclusion Criteria:\n\n          -  Treatment with Omega-3 fatty acid supplements for other reasons during the month\n             prior to inclusion in the trial\n\n          -  Treatment with acetylsalicylic acid (ASA), non-steroidal anti-inflammatory drugs\n             (NSAIDS), corticoids or thiazolidinedione antidiabetic drugs (glitazones)\n\n          -  Pregnant or nursing patients\n\n          -  Haemopathy, including clotting disorders\n\n          -  Treatment with dicoumarin anticoagulants (Sintrom\u00ae)\n\n          -  Cancer or a history of cancer who have not received the oncologist's release\n\n          -  Type 1 or type 2 diabetes mellitus\n\n          -  Immune disorders (rheumatoid arthritis, lupus, etc.) and/or inflammatory disease\n             (ulcerative colitis, Crohn's disease, etc.) that may alter the biological markers of\n             inflammation\n\n          -  Patients not expected to attend monitoring visits"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865448", 
            "org_study_id": "PNK-DHA-2013-01"
        }, 
        "intervention": {
            "arm_group_label": "omega-3 DHA", 
            "description": "Patients take daily 2 tablets of placebo", 
            "intervention_name": "Omega-3 DHA", 
            "intervention_type": "Dietary Supplement", 
            "other_name": [
                "Docosahexaenoic Acid", 
                "omega-3 fatty acid", 
                "PUFA"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Anti-Inflammatory Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Docosahexaenoic Acids", 
            "Fatty Acids, Omega-3", 
            "Obesity", 
            "Inflammation"
        ], 
        "lastchanged_date": "June 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Valladolid", 
                    "country": "Spain"
                }, 
                "name": "Research Support Unit. R\u00edo Hortega University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study to Assess the Effects of DHA (Docosahexaenoic Acid) on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment", 
        "overall_contact": {
            "email": "ignacio.s@pronokal.com", 
            "last_name": "Ignacio Sajoux, PhD", 
            "phone": "0034 666 988 021"
        }, 
        "overall_contact_backup": {
            "email": "montsevidal@puntaalta.es", 
            "last_name": "Montse Vidal, PhD", 
            "phone": "0034 663 825 890"
        }, 
        "overall_official": {
            "affiliation": "Unidad de Apoyo a la Investigacion. Hospital Rio Hortega", 
            "last_name": "Daniel De Luis, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Levels of 18 lipid mediators that are markers of inflammation and resolution", 
            "measure": "Levels of pro-resolving and anti-inflammatory lipid mediators", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865448"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline in level of biological markers of chronic inflammation", 
                "measure": "Biological markers of chronic inflammation", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change from Baseline in Weight during monitoring period", 
                "measure": "Change in weight", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change from baseline in body mass index during monitoring period", 
                "measure": "Change in body mass index", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change from Baseline in waist circumference during monitoring period", 
                "measure": "Change in waist circumference", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability of standardized weight-loss programme (PronoKal\u00ae Method)and Safety and Tolerability of DHA Supplements", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Protein Supplies SL", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Protein Supplies SL", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}